Polymun Scientific Immunbiologische Forschung GmbH

Among other activities Polymun is partner in the development and production of the first licensed Covid-19 vaccine Comirnaty (BioNTech/Pfizer). Due to its unique know-how and technology for the development and manufacturing of liposomal and lipid nanoparticle (LNP) formulations Polymun is among the most important companies concerning the development and production of Covid-19 vaccines on a worldwide scale.

Wall Street Journal: „If One Leading Coronavirus Vaccine Works, Thank This Tiny Firm in Rural Austria"

Polymun was founded in 1992 by Univ.-Prof. Dr. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal/LNP formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing.

Dietmar Katinger, CEO Polymun Scientific Immunbiologische Forschung GmbH

Dietmar Katinger studied biotechnology at the University of Life Sciences, Vienna. His thesis was related to the development of an influenza vaccine. He is CEO of Polymun Scientific Immunbiologische Forschung GmbH, developing and manufacturing biopharmaceuticals.

Q&A session

The presentation was followed by an online Q&A session. Dr. Katinger presented a power point about the company, its start of production of biopharmaceuticals at the site in Klosterneuburg near Vienna. Polymun specialized in the development and production of liposomal and LNP formulations as mentioned above. He informed about the cooparation with BioNTech receiving the RNA and Polymun manufacturing batches for the market supply. Since February 2020 Polymun started to produce preclinical and clinical batches. Despite of the rising need and consequently rising production Polymun does not plan to produce outside of Klosterneuburg. Excellent quality and reliability is the key to success. Polymun has a very experienced staff from Austria and surrounding countries, with little fluctuation. The cooperation with BioNTech continues on an excellent.